Related Experiment Video

Updated: Apr 19, 2026

Mixed Primary Cultures of Murine Small Intestine Intended for the Study of Gut Hormone Secretion and Live Cell Imaging of Enteroendocrine Cells
09:16

Mixed Primary Cultures of Murine Small Intestine Intended for the Study of Gut Hormone Secretion and Live Cell Imaging of Enteroendocrine Cells

Published on: April 20, 2017

16.3K

Glucagon-like peptide-1 receptor agonists across anti-inflammation

Daohong Chen1

  • 1Research Institute, Changshan Biochemical Pharmaceutical, 71 Menglong Street, Zhengding New District, Shijiazhuang, Hebei, 050800, China.

Molecular Aspects of Medicine
|April 17, 2026
PubMed

Insights

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) offer anti-inflammatory benefits beyond diabetes treatment. These drugs show potential for treating inflammatory conditions like cardiovascular disorders and neurodegenerative diseases.

Area of Science:

  • Pharmacology
  • Immunology
  • Endocrinology

Background:

  • Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are known for their anti-diabetic effects.
  • GLP-1RAs activate signaling pathways due to widespread receptor expression, influencing various biological roles.
  • Emerging research highlights the anti-inflammatory properties of GLP-1RAs, expanding their therapeutic potential.

Purpose of the Study:

  • To present a trending profile of inflammation-mediated diseases potentially alleviated by GLP-1 signaling augmentation.
  • To explore the synergistic cellular and molecular mechanisms of GLP-1RAs in modulating meta-inflammation and immuno-metabolism.
  • To highlight the translation of GLP-1 effects into clinical applications for inflammatory indications.

Main Methods:

  • Review of current literature on GLP-1 receptor agonist mechanisms.
  • Analysis of studies investigating GLP-1RA effects on inflammation-related diseases.
  • Systemic overview of multi-organ GLP-1 effects relevant to clinical practice.

Main Results:

  • GLP-1RAs demonstrate multifaceted biological roles beyond glucose regulation.
  • Pharmacological augmentation of GLP-1 signaling shows promise in managing meta-inflammation and immuno-metabolism.
  • Potential therapeutic benefits identified for cardiovascular disorders, metabolic associated steatohepatitis, neurodegenerative illness, arthritis, and inflammatory bowel disease.

Conclusions:

  • GLP-1 signaling modulation offers a promising therapeutic strategy for various inflammatory conditions.
  • The anti-inflammatory effects of GLP-1RAs are supported by their impact on meta-inflammation and immuno-metabolism.
  • Further clinical application of GLP-1RA medication for inflammatory indications is anticipated based on comprehensive multi-organ effects.
Keywords:
GLP-1RAMeta-inflammationTranslational pharmacology

More Related Videos

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis07:05

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Published on: May 12, 2019

6.7K
A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood11:36

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood

Published on: April 28, 2016

9.9K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.4K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
921
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1000
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
686
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
821